デフォルト表紙
市場調査レポート
商品コード
1377437

オピストルキス症治療市場- 世界の産業規模、シェア、動向、機会、および予測、2018年-2028年タイプ別、診断手順別、症状別、エンドユーザー別、地域別および競合別にセグメント化

Opisthorchiasis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type, By Diagnostic Procedure, By Symptom, By End User, By Region and Competition

出版日: | 発行: TechSci Research | ページ情報: 英文 190 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.52円

こちらのレポートには、数時間(ご購入金額の10%)分のアナリストへの質問/追加調査サービスが含まれております。

オピストルキス症治療市場- 世界の産業規模、シェア、動向、機会、および予測、2018年-2028年タイプ別、診断手順別、症状別、エンドユーザー別、地域別および競合別にセグメント化
出版日: 2023年10月03日
発行: TechSci Research
ページ情報: 英文 190 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 目次
概要

世界のオピストルキス症治療市場は予測期間中に目覚ましい成長を予測世界のオピストルキス症治療市場は、オピストルキス症と闘うための効果的な治療法とソリューションの提供に特化したヘルスケア産業の重要なセグメントです。

オピストルキス症は、タイ肝吸虫またはネコ肝吸虫によって引き起こされる寄生虫感染症です。この症状は、東欧やアジアの一部など、この病気が流行している地域では重大な健康上の懸念となっています。

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界オピストルキス症治療薬市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • タイプ別(投薬vs手術)
    • 診断方法別(胆管造影、MRI、超音波、CTスキャン、その他)
    • 症状別(黄疸、下痢、発熱、脾腫、体重減少、頻脈、その他)
    • エンドユーザー別(病院・クリニック、外来診療センター、その他)
    • 地域別
    • 企業別(2022年)
  • 市場マップ

第6章 北米オピストルキス症治療薬市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • タイプ別
    • 診断方法別
    • 症状別
    • エンドユーザー別
    • 国別
  • 北米国別分析
    • 米国
    • カナダ
    • メキシコ

第7章 欧州オピストルキス症治療薬市場の展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • タイプ別
    • 診断方法別
    • 症状別
    • エンドユーザー別
    • 国別
  • 欧州国別分析
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン

第8章 アジア太平洋オピストルキス症治療薬市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • タイプ別
    • 診断方法別
    • 症状別
    • エンドユーザー別
    • 国別
  • アジア太平洋地域国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第9章 南米オピストホルキアの治療市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • タイプ別
    • 診断方法別
    • 症状別
    • エンドユーザー別
    • 国別
  • 南米:国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカ喀痰喀出症治療薬市場の展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • タイプ別
    • 診断方法別
    • 症状別
    • エンドユーザー別
    • 国別
  • MEA:国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 最近の展開
  • 合併・買収
  • 製品発表

第13章 喀オピストルキス症治療の世界市場SWOT分析

第14章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第15章 競合情勢

  • Cipla Inc.
  • Johnson & Johnson
  • Sun Pharmaceutical Industries Ltd.
  • Merck KGaA
  • Boehringer Ingelheim International GmbH
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • F. Hoffmann-La Roche Ltd
  • AbbVie Inc
  • Mankind Pharma Limited

第16章 戦略的提言

第17章 調査会社について・免責事項

目次
Product Code: 8163

Global Opisthorchiasis Treatment Market is anticipated to project impressive growth in the forecast period. The global Opisthorchiasis Treatment Market is a vital segment of the healthcare industry, focusing specifically on providing effective therapies and solutions to combat opisthorchiasis. Opisthorchiasis is a parasitic infection caused by the Opisthorchis viverrini or Opisthorchis felineus flatworms. This condition poses a significant health concern in regions where it is endemic, such as parts of Eastern Europe and Asia.

The market offers a range of treatment options, including antiparasitic drugs, surgical interventions, and other therapeutic approaches. These treatments aim to alleviate symptoms, eradicate the parasite, and ultimately improve the quality of life for patients affected by opisthorchiasis. With advancements in medical research and innovation, the Opisthorchiasis Treatment Market continues to evolve, exploring new strategies and interventions to address this challenging condition. The market's growth is driven by the increasing prevalence of opisthorchiasis and the growing demand for effective treatment options. As healthcare professionals and researchers strive to enhance diagnostic techniques, develop novel therapies, and raise awareness about opisthorchiasis, the Opisthorchiasis Treatment Market plays a crucial role in ensuring access to effective treatments for those in need. By investing in research and development, fostering collaborations, and promoting education, this market contributes to the overall efforts in combating opisthorchiasis and improving public health on a global scale.

Key Market Drivers

Increased Consumption of Seafood in Raw Form

The increased consumption of seafood in raw or undercooked forms is indeed contributing to a heightened demand for opisthorchiasis treatment. Opisthorchiasis is a parasitic disease caused by the ingestion of raw or undercooked freshwater fish infected with the liver fluke Opisthorchis viverrini or Opisthorchis felineus. In regions where opisthorchiasis is endemic, consuming raw or partially cooked fish is a long-standing cultural practice. These traditions are deeply ingrained in the local cuisine, making it challenging to change dietary habits. As global travel and cuisine exchange have become more prevalent, raw seafood dishes like sushi and ceviche have gained popularity worldwide. This trend has led to an increased risk of opisthorchiasis in non-endemic areas.

In regions with limited food safety regulations or enforcement, there may be insufficient measures in place to ensure the safety of seafood products. This can result in a higher prevalence of contaminated fish in local markets. Changes in aquatic ecosystems, such as water pollution and alterations in the distribution of intermediate hosts (snails), can impact the prevalence of Opisthorchis infections in fish populations.The global trade in seafood products has expanded significantly, and contaminated fish can be distributed internationally. This can introduce opisthorchiasis to regions where it was previously rare or absent. To address the increased demand for opisthorchiasis treatment, public health efforts must focus on multiple fronts. This includes raising awareness about the risks associated with consuming raw or undercooked fish, implementing stricter food safety regulations, and promoting proper cooking practices. Additionally, research into more effective treatments and preventive measures remains crucial in tackling this parasitic disease in regions where raw seafood consumption is prevalent.

Growing Research and Development Activities for The Early Diagnosis

The surge in research and development activities aimed at early diagnosis is driving an increased demand for opisthorchiasis treatment. Opisthorchiasis, caused by the liver fluke Opisthorchis viverrini, is a parasitic disease primarily prevalent in parts of Southeast Asia and Eastern Europe. Ongoing research is leading to the development of more accurate and reliable diagnostic tests for opisthorchiasis. Newer serological tests, molecular assays, and imaging techniques are enhancing early detection, allowing for timely treatment and preventing disease progression. Early diagnosis enables healthcare providers to identify and treat cases at an earlier stage of infection. This not only benefits individual patients but also contributes to public health efforts to control the spread of opisthorchiasis.

Advanced diagnostic tools are reducing the time required to confirm opisthorchiasis infection. Early diagnosis is crucial, as it allows for the prompt initiation of treatment, minimizing the risk of severe complications. The growing emphasis on research and development activities for early diagnosis is fueling demand for opisthorchiasis treatment. These efforts are not only improving the accuracy and speed of diagnosis but also raising awareness about the disease, ultimately leading to better patient outcomes and enhanced public health efforts to combat opisthorchiasis in affected regions.

Increasing Demand for Healthcare Services and Treatments

The increasing demand for healthcare services and treatments is significantly contributing to the rising demand for opisthorchiasis treatment. Opisthorchiasis, a parasitic infection caused by liver flukes like Opisthorchis viverrini, remains a significant public health concern.

As healthcare services become more accessible and widespread, more individuals have the opportunity to seek medical attention. This increased access results in more people being diagnosed with opisthorchiasis and subsequently requiring treatment. Rising demand for healthcare services is often coupled with increased awareness and education about health issues, including the risks associated with opisthorchiasis. This heightened awareness encourages individuals to seek medical assistance, leading to greater demand for treatment.

Globalization and increased mobility have led to population movements between endemic and non-endemic regions. Individuals who contract opisthorchiasis in their home countries may seek treatment in areas with more advanced healthcare systems, further driving the demand for opisthorchiasis treatment. Opisthorchiasis can often co-occur with other health issues, such as liver disease and bile duct cancer. As healthcare providers screen for these conditions and identify opisthorchiasis cases, more individuals require treatment to manage co-infections and complications. Growing demand for healthcare services prompts governments and organizations to invest in public health initiatives. These programs include mass screenings and treatment campaigns, further increasing the number of individuals receiving opisthorchiasis treatment.

The Emergence of New Technologies, And Rising Innovation

The emergence of new technologies and rising innovation in the field of healthcare are playing a pivotal role in increasing the demand for opisthorchiasis treatment. Opisthorchiasis, a parasitic infection caused by the liver fluke Opisthorchis viverrini, primarily affects people in Southeast Asia and parts of Eastern Europe. Innovative diagnostic tools, such as molecular assays and imaging techniques like ultrasound and MRI, are enhancing the accuracy and speed of opisthorchiasis diagnosis. Early and precise diagnosis is crucial for timely treatment and preventing disease complications, prompting greater demand for treatment. Advances in pharmaceutical research are leading to the development of more targeted and effective drugs for treating opisthorchiasis. These innovations are driving demand by offering improved treatment options with fewer side effects and shorter treatment durations.

Technological innovations, such as mobile health apps and online resources, empower patients to take control of their health and seek treatment when necessary. This increased patient engagement contributes to the growing demand for opisthorchiasis treatment. The emergence of new technologies and rising innovation in healthcare are driving demand for better opisthorchiasis treatment options. These advancements are not only improving the accuracy of diagnosis and treatment but also increasing awareness about the disease, ultimately leading to better outcomes for those affected by opisthorchiasis.

Key Market Challenges

Lack Of Awareness About the Disease

The growth of effective treatments for opisthorchiasis, a neglected tropical disease, has been significantly hindered by a lack of awareness about the disease. Opisthorchiasis, often overlooked in public health agendas, is primarily transmitted through the consumption of raw or undercooked fish, which is a staple of many diets in endemic regions. Unfortunately, this lack of knowledge about the disease's transmission mode often leads to unaffected prevention measures.

Furthermore, the symptoms of opisthorchiasis, such as abdominal discomfort, diarrhea, and malaise, are often mild and non-specific, making it challenging for healthcare professionals to diagnose accurately. This lack of awareness among healthcare professionals further complicates the treatment landscape, as the disease is often not considered in differential diagnoses.

Moreover, the absence of large-scale public health campaigns focusing on opisthorchiasis contributes to the disease's invisibility. Many people in endemic areas remain unaware of the disease, its transmission modes, its symptoms, and the importance of seeking medical help upon noticing these symptoms. To address these challenges, raising awareness about opisthorchiasis is a crucial step in its treatment. Efforts should be directed towards comprehensive public health campaigns, educating the public about the disease, its transmission, and the importance of seeking early medical intervention. Moreover, proper training of healthcare professionals is essential to accurately diagnose and treat this neglected tropical disease. Only through these collective efforts can the growth of effective treatments for opisthorchiasis be truly realized.

Limited Availability and Accessibility Of Diagnostic Services

The global opisthorchiasis treatment market is undergoing significant challenges, primarily due to the limited availability and accessibility of diagnostic services, thereby impeding its growth. Opisthorchiasis, a parasitic disease prevalent in regions such as Southeast Asia and Eastern Europe, requires accurate and efficient diagnosis to facilitate timely and effective treatment. However, diagnostic services for this parasitic infection are not widely available, especially in rural and remote settings where the disease is most widespread. The need for specialized lab equipment and trained professionals for diagnosis further exacerbates the problem. These factors contribute to the underdiagnosis and, consequently, undertreatment of opisthorchiasis, impeding the growth of the treatment market. Moreover, accessibility to diagnostic services is another major barrier. Many affected individuals reside in low-income, hard-to-reach areas. The lack of transport infrastructure coupled with the high cost associated with diagnosis and treatment, make it practically impossible for these individuals to access much-needed healthcare services.

Efforts to expand the availability of diagnostic services are crucial. Greater government funding, partnership with NGOs, and incentivizing private sector involvement can boost service availability. Additionally, implementing mobile health clinics and telemedicine could improve accessibility, particularly in remote areas. Limited diagnostic service availability and accessibility are significant obstacles to the growth of the global opisthorchiasis treatment market. Addressing these problems requires strategic initiatives aimed at improving healthcare access and affordability, particularly in areas where the disease is rampant.

Key Market Trends

Increased Investment in Research and Development

Advancements in diagnostic tools, such as high-tech imaging techniques and precise laboratory tests, are set to play a pivotal role in the growth of the global opisthorchiasis treatment market. These state-of-the-art diagnostic methods enable early detection of the parasitic infection, allowing for more effective and targeted treatments. By identifying the presence of opisthorchiasis at an early stage, healthcare professionals can intervene promptly and provide timely interventions, resulting in quicker patient recovery and improved outcomes.

Moreover, the implementation of advanced diagnostic technologies not only helps in reducing the impact and prevalence of the disease, but also minimizes the risk of complications associated with advanced stages of opisthorchiasis. By detecting the infection before it progresses, healthcare providers can prevent further damage to the liver and other organs, leading to better long-term health outcomes for patients.

Given the significant benefits of early detection and treatment, there is a growing focus on investments and innovations in diagnostic technology within the global opisthorchiasis treatment market. The development of more accurate, efficient, and accessible diagnostic tools holds great promise in improving patient care and addressing the global burden of opisthorchiasis.

Advancements In Diagnostic Tools for Early Detection

Advancements in diagnostic tools for the early detection of opisthorchiasis are expected to have a profound impact on the global opisthorchiasis treatment market. By enabling the identification of the disease at its early stages, these tools facilitate prompt and effective treatment, leading to a decrease in the prevalence and severity of late-stage complications. Moreover, the improved precision and speed of these diagnostic tools ensure that a larger number of patients can be accurately diagnosed and promptly treated, resulting in an increased demand for treatment modalities and medications. Consequently, these advancements are poised to not only bolster the market but also create a higher demand and accelerate the overall growth of the opisthorchiasis treatment sector. With the potential to revolutionize the diagnosis and management of opisthorchiasis, these innovative tools pave the way for a brighter future in combating this debilitating disease.

Segmental Insights

Diagnostic Procedure Insights

Based on the diagnostic procedure, the Cholangiography segment is expected to continue its dominance in the global opisthorchiasis treatment market. This is primarily due to the widespread adoption of standardized stool examination techniques, which have greatly improved the accuracy and reliability of diagnosing opisthorchiasis. As a result, there has been a significant increase in demand for cholangiography procedures, as healthcare professionals recognize the value and effectiveness of this diagnostic method in effectively managing and treating opisthorchiasis cases. With its ability to provide detailed imaging of the bile ducts, cholangiography plays a crucial role in guiding treatment decisions and ensuring optimal patient outcomes.

End User Insights

Based on end user, the market is fragmented into hospitals & clinics, ambulatory care centres, and others. The hospitals and clinics segment is projected to maintain its dominance in the global opisthorchiasis treatment market. This is primarily attributed to their exceptional ability to provide state-of-the-art medical equipment, advanced products, and comprehensive services that cater specifically to the unique needs of patients. With their cutting-edge facilities, highly skilled healthcare professionals, and unwavering patient-centric approach, hospitals and clinics play a vital role in ensuring not only the accurate diagnosis, effective treatment, and efficient management of opisthorchiasis but also in contributing significantly to the overall growth of the market. Their continuous efforts and commitment to delivering exceptional healthcare services make them pivotal players in the battle against opisthorchiasis, ultimately improving the quality of life for those affected.

Regional Insights

The Asia-Pacific region is currently leading the global opisthorchiasis treatment market. This dominance is primarily attributed to the endemic nature of the disease in this area, specifically in countries located within the Mekong river basin, such as Thailand, Laos, and Cambodia. The unique geographical and environmental factors in these countries create favorable conditions for the transmission and prevalence of opisthorchiasis, leading to a higher demand for treatment options.

Furthermore, the region's market dominance can also be attributed to increased healthcare expenditures aimed at tackling the disease burden and improving access to effective treatment. Governments and healthcare organizations within the Asia-Pacific region have prioritized the allocation of resources towards opisthorchiasis prevention, diagnosis, and treatment initiatives. This proactive approach has not only contributed to the region's market dominance but has also raised awareness about the disease among healthcare professionals and the general population.

Asia-Pacific region's leading position in the global opisthorchiasis treatment market is a result of multiple factors, including the endemic nature of the disease, increased healthcare expenditures, and growing awareness about opisthorchiasis. These factors collectively create a favorable environment for the development and adoption of innovative treatment solutions, making the region a key player in addressing the challenges posed by this disease.

Key Market Players

Cipla Inc.

Johnson & Johnson

Sun Pharmaceutical Industries Ltd.

Merck KGaA

Boehringer Ingelheim International GmbH

Pfizer Inc.

GlaxoSmithKline plc

F. Hoffmann-La Roche Ltd

AbbVie Inc

Mankind Pharma Limited

Report Scope:

In this report, the Global Opisthorchiasis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Opisthorchiasis Treatment Market, By Type:

  • Medications
  • Surgery

Opisthorchiasis Treatment Market, By Diagnostic Procedure:

  • Cholangiography
  • MRI
  • Ultrasonography
  • CT scan
  • Others

Opisthorchiasis Treatment Market, By Symptom:

  • Jaundice
  • Diarrhea
  • Fever
  • Splenomegaly
  • Weight loss
  • Tachycardia
  • Others

Opisthorchiasis Treatment Market, By End User:

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Opisthorchiasis Treatment Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Opisthorchiasis Treatment Market.

Available Customizations:

  • Global Opisthorchiasis Treatment market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Opisthorchiasis Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Medications v/s Surgery)
      • 5.2.1.1. By Medications (Antibiotics, Anthelmintics, Others)
    • 5.2.2. By Diagnostic Procedure (Cholangiography, MRI, Ultrasonography, CT scan, Others)
    • 5.2.3. By Symptom (Jaundice, Diarrhea, Fever, Splenomegaly, Weight loss, Tachycardia, Others)
    • 5.2.4. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2022)
  • 5.3. Market Map

6. North America Opisthorchiasis Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Diagnostic Procedure
    • 6.2.3. By Symptom
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Opisthorchiasis Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Diagnostic Procedure
        • 6.3.1.2.3. By Symptom
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada Opisthorchiasis Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Diagnostic Procedure
        • 6.3.2.2.3. By Symptom
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico Opisthorchiasis Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Diagnostic Procedure
        • 6.3.3.2.3. By Symptom
        • 6.3.3.2.4. By End User

7. Europe Opisthorchiasis Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Diagnostic Procedure
    • 7.2.3. By Symptom
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Opisthorchiasis Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Diagnostic Procedure
        • 7.3.1.2.3. By Symptom
        • 7.3.1.2.4. By End User
    • 7.3.2. United Kingdom Opisthorchiasis Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Diagnostic Procedure
        • 7.3.2.2.3. By Symptom
        • 7.3.2.2.4. By End User
    • 7.3.3. Italy Opisthorchiasis Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Diagnostic Procedure
        • 7.3.3.2.3. By Symptom
        • 7.3.3.2.4. By End User
    • 7.3.4. France Opisthorchiasis Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Diagnostic Procedure
        • 7.3.4.2.3. By Symptom
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Opisthorchiasis Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Diagnostic Procedure
        • 7.3.5.2.3. By Symptom
        • 7.3.5.2.4. By End User

8. Asia-Pacific Opisthorchiasis Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Diagnostic Procedure
    • 8.2.3. By Symptom
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Opisthorchiasis Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Diagnostic Procedure
        • 8.3.1.2.3. By Symptom
        • 8.3.1.2.4. By End User
    • 8.3.2. India Opisthorchiasis Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Diagnostic Procedure
        • 8.3.2.2.3. By Symptom
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan Opisthorchiasis Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Diagnostic Procedure
        • 8.3.3.2.3. By Symptom
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea Opisthorchiasis Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Diagnostic Procedure
        • 8.3.4.2.3. By Symptom
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Opisthorchiasis Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Diagnostic Procedure
        • 8.3.5.2.3. By Symptom
        • 8.3.5.2.4. By End User

9. South America Opisthorchiasis Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Diagnostic Procedure
    • 9.2.3. By Symptom
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Opisthorchiasis Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Diagnostic Procedure
        • 9.3.1.2.3. By Symptom
        • 9.3.1.2.4. By End User
    • 9.3.2. Argentina Opisthorchiasis Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Diagnostic Procedure
        • 9.3.2.2.3. By Symptom
        • 9.3.2.2.4. By End User
    • 9.3.3. Colombia Opisthorchiasis Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Diagnostic Procedure
        • 9.3.3.2.3. By Symptom
        • 9.3.3.2.4. By End User

10. Middle East and Africa Opisthorchiasis Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Diagnostic Procedure
    • 10.2.3. By Symptom
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Opisthorchiasis Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Diagnostic Procedure
        • 10.3.1.2.3. By Symptom
        • 10.3.1.2.4. By End User
    • 10.3.2. Saudi Arabia Opisthorchiasis Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Diagnostic Procedure
        • 10.3.2.2.3. By Symptom
        • 10.3.2.2.4. By End User
    • 10.3.3. UAE Opisthorchiasis Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Diagnostic Procedure
        • 10.3.3.2.3. By Symptom
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Global Opisthorchiasis Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Service Offerings
  • 15.3. Recent Developments
  • 15.4. Key Personnel
  • 15.5. SWOT Analysis
    • 15.5.1. Cipla Inc.
    • 15.5.2. Johnson & Johnson
    • 15.5.3. Sun Pharmaceutical Industries Ltd.
    • 15.5.4. Merck KGaA
    • 15.5.5. Boehringer Ingelheim International GmbH
    • 15.5.6. Pfizer Inc.
    • 15.5.7. GlaxoSmithKline plc
    • 15.5.8. F. Hoffmann-La Roche Ltd
    • 15.5.9. AbbVie Inc
    • 15.5.10. Mankind Pharma Limited

16. Strategic Recommendations

17. About Us & Disclaimer